Danaher (NYSE:DHR) PT Lowered to $277.00

Danaher (NYSE:DHR) had its target price lowered by equities researchers at Robert W. Baird from $278.00 to $277.00 in a report released on Wednesday, Benzinga reports. The firm currently has an “outperform” rating on the conglomerate’s stock. Robert W. Baird’s price target points to a potential upside of 11.75% from the stock’s previous close.

Other equities analysts also recently issued research reports about the stock. TD Cowen raised their price objective on shares of Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a report on Wednesday, July 24th. Royal Bank of Canada reiterated an “outperform” rating and set a $300.00 price target on shares of Danaher in a research note on Friday, September 6th. Stifel Nicolaus upped their price objective on Danaher from $235.00 to $250.00 and gave the stock a “hold” rating in a research note on Wednesday, July 24th. The Goldman Sachs Group lifted their target price on Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a research report on Wednesday, July 24th. Finally, Evercore ISI upped their price target on Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Seven analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $287.28.

Danaher Trading Down 3.2 %

Shares of DHR stock opened at $247.88 on Wednesday. The stock has a market capitalization of $183.60 billion, a P/E ratio of 42.01, a P/E/G ratio of 4.49 and a beta of 0.83. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. The firm’s 50 day moving average is $270.43 and its 200 day moving average is $260.43. Danaher has a 12-month low of $182.09 and a 12-month high of $281.70.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping the consensus estimate of $1.57 by $0.14. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The company had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same quarter in the previous year, the company posted $2.02 earnings per share. Danaher’s revenue was up 3.1% compared to the same quarter last year. Research analysts expect that Danaher will post 7.59 earnings per share for the current year.

Insiders Place Their Bets

In related news, CFO Matthew Mcgrew sold 16,172 shares of the firm’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total value of $4,525,572.48. Following the completion of the transaction, the chief financial officer now directly owns 29,407 shares of the company’s stock, valued at approximately $8,229,254.88. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the transaction, the senior vice president now owns 4,212 shares in the company, valued at approximately $1,130,374.44. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Matthew Mcgrew sold 16,172 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total value of $4,525,572.48. Following the sale, the chief financial officer now owns 29,407 shares in the company, valued at approximately $8,229,254.88. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 30,059 shares of company stock valued at $8,400,897 in the last quarter. 11.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Danaher

Large investors have recently modified their holdings of the stock. AdvisorNet Financial Inc increased its position in Danaher by 11.3% during the first quarter. AdvisorNet Financial Inc now owns 758 shares of the conglomerate’s stock valued at $189,000 after acquiring an additional 77 shares during the last quarter. Dynamic Advisor Solutions LLC grew its holdings in Danaher by 8.3% during the 1st quarter. Dynamic Advisor Solutions LLC now owns 7,744 shares of the conglomerate’s stock valued at $1,934,000 after purchasing an additional 591 shares during the last quarter. Procyon Advisors LLC raised its position in Danaher by 14.0% in the 1st quarter. Procyon Advisors LLC now owns 8,789 shares of the conglomerate’s stock worth $2,195,000 after purchasing an additional 1,082 shares during the period. Wealth Enhancement Advisory Services LLC lifted its stake in Danaher by 3.8% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 194,515 shares of the conglomerate’s stock worth $48,574,000 after purchasing an additional 7,076 shares during the last quarter. Finally, Thrive Wealth Management LLC grew its stake in shares of Danaher by 4.9% during the first quarter. Thrive Wealth Management LLC now owns 6,070 shares of the conglomerate’s stock valued at $1,516,000 after buying an additional 283 shares during the last quarter. Institutional investors own 79.05% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.